RE: PK study6 Sep 2021 20:10
Dh1233,
You seem to be very pessimistic to say the least judging by your posting history
Avion29 Nov 2019 13:35
Perhaps I'm being cynical after years of disappointment but I'm not very impressed with Avion's website and I wonder if they can pull this off. Clearly they can't afford an upfront payment to IMM and doubt if they can design or run a complex P3 trial. Can someone please tell me why a pharma who's only products are dietary supplements and a dermatology product who focus on women's health and dermatology have a "specialist sales team who are well respected within the rheumatologist community" - they attended their first rheumatology conference 2 weeks ago to promote their plant alkaloid product for gout flares but have nothing for rheumatoid auto-immune diseases. From a quick look on LinkedIn, their 'sales reps' are all twenty-somethings with little or no pharma experience and Art Deas, CEO, is only listed as CEO of Acella - a similar looking company to Avion owned by the same parent company - Alora - and no announcement of the IMM deal on any or their websites..
I wonder why ….